169 related articles for article (PubMed ID: 16269594)
41. Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma.
Krasner C; Joyce RM
Curr Pharm Biotechnol; 2001 Dec; 2(4):341-9. PubMed ID: 11762415
[TBL] [Abstract][Full Text] [Related]
42. Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (
Wahl RL; Frey EC; Jacene HA; Kahl BS; Piantadosi S; Bianco JA; Hammes RJ; Jung M; Kasecamp W; He B; Sgouros G; Flinn IW; Swinnen LJ
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34204102
[TBL] [Abstract][Full Text] [Related]
43. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
Wiseman GA; Witzig TE
Cancer Biother Radiopharm; 2005 Apr; 20(2):185-8. PubMed ID: 15869453
[TBL] [Abstract][Full Text] [Related]
44. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice.
Jacene HA; Filice R; Kasecamp W; Wahl RL
J Nucl Med; 2007 Nov; 48(11):1767-76. PubMed ID: 17942813
[TBL] [Abstract][Full Text] [Related]
45. Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin).
Hernandez MC; Knox SJ
Semin Oncol; 2003 Dec; 30(6 Suppl 17):6-10. PubMed ID: 14710397
[TBL] [Abstract][Full Text] [Related]
46. Zevalin(®) (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?
Rizzieri D
Crit Rev Oncol Hematol; 2016 Sep; 105():5-17. PubMed ID: 27497027
[TBL] [Abstract][Full Text] [Related]
47. Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.
Weigert O; Illidge T; Hiddemann W; Dreyling M
Cancer; 2006 Aug; 107(4):686-95. PubMed ID: 16826593
[TBL] [Abstract][Full Text] [Related]
48. FDG PET CT assessment of treatment response after yttrium-90 ibritumomab tiuxetan radioimmunotherapy.
Joyce JM; Degirmenci B; Jacobs S; McCook B; Avril N
Clin Nucl Med; 2005 Aug; 30(8):564-8. PubMed ID: 16024958
[TBL] [Abstract][Full Text] [Related]
49. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma.
Wiseman GA; Leigh B; Erwin WD; Lamonica D; Kornmehl E; Spies SM; Silverman DH; Witzig TE; Sparks RB; White CA
Cancer; 2002 Feb; 94(4 Suppl):1349-57. PubMed ID: 11877765
[TBL] [Abstract][Full Text] [Related]
50. Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma.
Doolittle ND; Jahnke K; Belanger R; Ryan DA; Nance RW; Lacy CA; Tyson RM; Haluska M; Hedrick NA; Varallyay C; Neuwelt EA
Leuk Lymphoma; 2007 Sep; 48(9):1712-20. PubMed ID: 17786706
[TBL] [Abstract][Full Text] [Related]
51. Radiation safety guidelines for radioimmunotherapy with yttrium 90 ibritumomab tiuxetan.
Hendrix C
Clin J Oncol Nurs; 2004 Feb; 8(1):31-4. PubMed ID: 14983760
[TBL] [Abstract][Full Text] [Related]
52. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.
Shimoni A; Zwas ST; Oksman Y; Hardan I; Shem-Tov N; Yerushalmi R; Avigdor A; Ben-Bassat I; Nagler A
Exp Hematol; 2007 Apr; 35(4):534-40. PubMed ID: 17379063
[TBL] [Abstract][Full Text] [Related]
53. Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma.
Scheidhauer K; Wolf I; Baumgartl HJ; Von Schilling C; Schmidt B; Reidel G; Peschel C; Schwaiger M
Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1276-82. PubMed ID: 12271407
[TBL] [Abstract][Full Text] [Related]
54. History of antibody therapy for non-Hodgkin's lymphoma.
Forero A; Lobuglio AF
Semin Oncol; 2003 Dec; 30(6 Suppl 17):1-5. PubMed ID: 14710396
[TBL] [Abstract][Full Text] [Related]
55. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
56. Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results.
Chiesa C; Botta F; Di Betta E; Coliva A; Maccauro M; Aliberti G; Bavusi S; Devizzi L; Guidetti A; Seregni E; Gianni AM; Bombardieri E
Cancer Biother Radiopharm; 2007 Feb; 22(1):113-20. PubMed ID: 17627419
[TBL] [Abstract][Full Text] [Related]
57. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.
Zinzani PL; Tani M; Fanti S; Stefoni V; Musuraca G; Vitolo U; Perrotti A; Fina M; Derenzini E; Baccarani M
Cancer; 2008 Feb; 112(4):856-62. PubMed ID: 18189293
[TBL] [Abstract][Full Text] [Related]
58. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome.
Tsimberidou AM; Murray JL; O'Brien S; Wierda WG; Keating MJ
Cancer; 2004 May; 100(10):2195-200. PubMed ID: 15139064
[TBL] [Abstract][Full Text] [Related]
59. Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma.
Assié K; Dieudonné A; Gardin I; Buvat I; Tilly H; Vera P
Cancer Biother Radiopharm; 2008 Feb; 23(1):53-64. PubMed ID: 18298329
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
